Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005001 · ClinicalTrials.gov registry record · Phase 2
Safety and Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)
A Phase 2 study, sponsored by Agouron Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00005001: Completed Phase 2 study, sponsored by Agouron Pharmaceuticals.
NCT00005001 is a Phase 2 study that has completed, run by Agouron Pharmaceuticals. The registered enrollment target is 40 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005001, a Phase 2 study, has completed, sponsored by Agouron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to see if giving HIV-positive patients an HIV vaccine plus anti-HIV drugs can help lower HIV levels in the blood (viral load).
Interventions
- BIOLOGICAL HIV-1 Immunogen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Phase | Phase 2 |
What the finished NCT00005001 record still lists
NCT00005001 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 1 intervention - of which HIV-1 Immunogen is the first listed.
NCT00005001 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00005001 about?
NCT00005001 is a clinical study titled "Safety and Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)". The purpose of this study is to see if giving HIV-positive patients an HIV vaccine plus anti-HIV drugs can help lower HIV levels in the blood (viral load).
What is the current status of trial NCT00005001?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants.
What interventions are being tested in trial NCT00005001?
The interventions under investigation include: HIV-1 Immunogen (BIOLOGICAL).
Who is sponsoring clinical trial NCT00005001?
This trial is sponsored by Agouron Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00005001's enrollment target sits among peer trials
40 1362nd of 2000 higher than 542 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models